Investidor Profissional Gestao de Recursos Ltda. Makes New $491,000 Investment in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Investidor Profissional Gestao de Recursos Ltda. purchased a new position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 1,188 shares of the company's stock, valued at approximately $491,000. IDEXX Laboratories makes up about 0.3% of Investidor Profissional Gestao de Recursos Ltda.'s portfolio, making the stock its 14th biggest holding.

Other large investors also recently added to or reduced their stakes in the company. Public Sector Pension Investment Board raised its position in IDEXX Laboratories by 16.2% during the 3rd quarter. Public Sector Pension Investment Board now owns 3,578 shares of the company's stock valued at $1,808,000 after purchasing an additional 500 shares during the last quarter. Benjamin Edwards Inc. increased its holdings in shares of IDEXX Laboratories by 661.1% during the third quarter. Benjamin Edwards Inc. now owns 1,880 shares of the company's stock valued at $950,000 after acquiring an additional 1,633 shares in the last quarter. Centiva Capital LP bought a new position in shares of IDEXX Laboratories in the third quarter worth approximately $211,000. Janus Henderson Group PLC increased its position in shares of IDEXX Laboratories by 0.4% during the third quarter. Janus Henderson Group PLC now owns 11,834 shares of the company's stock valued at $5,978,000 after acquiring an additional 53 shares in the last quarter. Finally, IHT Wealth Management LLC raised its holdings in shares of IDEXX Laboratories by 32.9% during the third quarter. IHT Wealth Management LLC now owns 666 shares of the company's stock valued at $335,000 after purchasing an additional 165 shares during the last quarter. Hedge funds and other institutional investors own 87.84% of the company's stock.

Remove Ads

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on IDXX. StockNews.com upgraded shares of IDEXX Laboratories from a "hold" rating to a "buy" rating in a research report on Friday, April 4th. Morgan Stanley cut their price target on shares of IDEXX Laboratories from $559.00 to $550.00 and set an "overweight" rating on the stock in a report on Wednesday, January 29th. Piper Sandler upped their price target on shares of IDEXX Laboratories from $435.00 to $510.00 and gave the stock a "neutral" rating in a report on Monday, February 10th. Barclays raised their target price on shares of IDEXX Laboratories from $481.00 to $520.00 and gave the company an "overweight" rating in a research report on Tuesday, February 4th. Finally, Bank of America lifted their price target on shares of IDEXX Laboratories from $475.00 to $535.00 and gave the stock a "neutral" rating in a report on Tuesday, February 4th. Three research analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $533.75.

Insider Activity at IDEXX Laboratories

In related news, Director M Anne Szostak sold 3,000 shares of the business's stock in a transaction on Friday, February 7th. The stock was sold at an average price of $465.94, for a total value of $1,397,820.00. Following the sale, the director now owns 3,061 shares in the company, valued at approximately $1,426,242.34. The trade was a 49.50 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP George Fennell sold 9,986 shares of the business's stock in a transaction dated Monday, February 10th. The stock was sold at an average price of $462.53, for a total value of $4,618,824.58. Following the transaction, the executive vice president now directly owns 8,176 shares of the company's stock, valued at approximately $3,781,645.28. This represents a 54.98 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 2.11% of the company's stock.

IDEXX Laboratories Price Performance

Shares of NASDAQ IDXX traded down $13.57 during mid-day trading on Thursday, reaching $383.54. The company's stock had a trading volume of 680,141 shares, compared to its average volume of 609,647. The stock has a market capitalization of $31.08 billion, a P/E ratio of 35.74, a P/E/G ratio of 3.41 and a beta of 1.50. The company has a debt-to-equity ratio of 0.28, a quick ratio of 0.95 and a current ratio of 1.31. IDEXX Laboratories, Inc. has a 1-year low of $356.14 and a 1-year high of $548.88. The stock has a 50-day moving average of $431.26 and a two-hundred day moving average of $435.73.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.